1 Bauer JH, Reams GP. The angiotensin Ⅱ type I receptor antagonists: a new classs of antihypertensive drugs. Arch Intern Med, 1995; 155: 1361
2 Timmermans P, Benfield P, CHiu AT, et al. Angiotensin Ⅱ receptors and angiotensin Ⅱ receptor antagonists. Pharmacov Rev, 1993; 45: 205
3 De Leeuw PW. How do angiotensin Ⅱ receptor antagonists affect blood pressure? Am J Cardiol, 1999; 84: 5K
4 Brooks DP, Ohlstein EH, Ruffolo RR, et al. Pharmacology of eprosartan, an angiotensin Ⅱ recaptor ntagonist: exploring hypotheses from clinical data. Am Heart J, 1999; 138: S 246
5 过鑫昌. 血管紧张素Ⅱ受体拮抗剂临床应用研究进展. 国外医药——合成药生化药制剂分册, 1999; 20(6):334
6 Goa KL,Wag staff AT. Losartan potassium, are view of its pharmacology, clinical efficacy and to lerability in the management of hypertension. Drugs, 1996; 51(5): 821
7 Markham A, Karen LG. Valsartan, are view of its pharmacology and therapeutic use in essential hypertension. Drugs, 1997; 54(2):299
8 黄洁, 郭冀珍, 陶萍, 等.氯沙坦治疗轻、中度高血压病的疗效和安全性评价.中华心血管病杂志, 1999; 27(3): 196
9 Zanchetti A. Impact of hyper tension and antihypertensive treatment on org an damage. Am J Cardiol, 1999; 84: 18K
10 Pitt B, Segal R, Martinez FA, et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the elderly study, ELITE). Lancet, 1997; 349(9054): 747
11 王晓阳, 丁文惠, 吴林, 等.血管紧张素ⅡI型受体拮抗剂氯沙坦对急性心肌梗死的血流动力学效应.中国医药导刊, 1999; 1(1): 29
12 Bohm M, Lippoldt A, Wienen W, et al. Reduction of cardiac hyper trophy in TGR (mRenz) 27 by angiotensin Ⅱ receptor blockade. Mol Cell Biochem,1996; 163/164: 217
13 章建梁, 章国华, 杨尚祥, 等.血管紧张素Ⅱ受体拮抗剂对高血压冠状动脉肥厚和功能异常的影响.临床心血管病杂志, 1999; 15(10):450 |
